A collaborative outcome study in uveal melanoma with the US National Cancer Institute’s Surveillance, Epidemiology, and End Results Program Registries (NCI SEER): Performance of the 15-gene expression profile test in prospectively tested uveal melanoma patients (Analysis 1)

Katherine M Alsina, PhD1, Sarah J Kurley, PhD1, Christine N Bailey, MPH2, Kelli LAhmed, PhD3, Valentina I Petkov, MD, MPH2, Jason H Rogers, MSc1, Kyle R Covington, PhD1, and Robert W Cook, PhD1

1Castle Biosciences, Inc. Friendswood, Texas, USA 2National Cancer Institute, Surveillance Research Program. Bethesda, Maryland, USA

Results

Patients with a 15-GEP Class 1A result had higher 18-month OS than patients with a Class 2 result (97% vs. 66%; P=0.02) (Figure 1).

Figure 1. Overall survival of 15-GEP-tested uveal melanoma patients in the NCI SEER registry

Results: Survival

Table 2. Univariate analysis by GEP Class result (n=255)

<table>
<thead>
<tr>
<th>Group</th>
<th>No. at risk</th>
<th>18-month MSS (95% CI)</th>
<th>Deaths, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class 1A</td>
<td>125</td>
<td>98.9% (96.7-100%)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Class 1B</td>
<td>88</td>
<td>98.1% (94.6-100%)</td>
<td>1 (1.1)</td>
</tr>
<tr>
<td>Class 2</td>
<td>50</td>
<td>92.7% (86.7-99.1%)</td>
<td>1 (8.3)</td>
</tr>
</tbody>
</table>

*P value calculated by log rank test

Conclusions

Consistent with previously published cohorts, the 15-GEP accurately stratified risk of death from uveal melanoma in this unselected, real-world contemporary cohort.

Future analyses of NCI SEER-linked uveal melanoma patient data will include patients with 15-GEP results who were diagnosed as far back as 2009, which will provide an even larger cohort with more extensive follow-up time.

References


Acknowledgments & Disclosures

This study was supported by Castle Biosciences, Inc. in collaboration with the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program Registries (NCI SEER). For more information visit https://seer.cancer.gov/

KMA, SJK, CNB, KLA, JHR, KRC, and RWC are employees and shareholders of Castle Biosciences, Inc. VHP has no computing financial interests to disclose.

Presented at the 19th International Congress of the Society for Melanoma Research (SMR) 2022 in Edinburgh, Scotland; 17-22 October 2022. Poster #P-035